Navigation Links
Urigen Announces Issuance of Key Patent for URG101 - A Novel Therapy to Treat Painful Bladder Syndrome/Interstitial Cystitis
Date:8/19/2008

BURLINGAME, Calif., August 19 /PRNewswire-FirstCall/ -- Urigen Pharmaceuticals, Inc. (OTC Bulletin Board: URGP, http://www.urigen.com), a specialty pharmaceutical company focused on the development and commercialization of treatments for urological disorders, today announced the U.S. Patent and Trademark Office has issued the first patent for the use of URG101, an investigational, bladder instillation treatment for Painful Bladder Syndrome/Interstitial Cystitis (PBS/IC). Patent number US 7,414,039 broadly covers the use of the URG101 product in the treatment of PBS/IC. The term of the patent extends into 2025.

"Not only does this patent establish protection for the use of URG101 in Painful Bladder Syndrome and Interstitial Cystitis; it also validates the excellent intellectual property guidance provided by Tom Jurgensen, JD of Catalyst Law and Stephen Reiter, PhD, JD of Foley & Lardner," stated William J. Garner, MD, President and CEO of Urigen. "We will continue to execute our intellectual property strategy to strengthen our proprietary position in the field of PBS/IC."

Urigen has announced positive results from a Phase 2 study of URG101. The study was a multi-center, double-blind, placebo-controlled, crossover trial. Findings from the study included:

-- Primary Endpoint -- Improvement in Average Daytime Pain (p=0.03).

-- Secondary Endpoints -- Improvement in Daytime Urgency (p=0.03) and Total Symptom Score (p=0.03). In addition, patients reported improved symptom relief with URG101 as measured by PORIS (p=0.01).

About URG101

URG101 is a pharmaceutical treatment for Painful Bladder Syndrome/Interstitial Cystitis that is instilled into the bladder. URG101 works with lidocaine reducing the sensations of pain, urge and muscle spasms and heparin, a glycosaminoglycan, coating the bladder wall thus augmenting the natural heparinoids.

About Painful Bladder Syndrome/Interstitial Cystitis (PBS)

Painful Bladder Syndrome/Interstitial Cystitis is a recognized medical condition with increased frequency of diagnosis. PBS/IC is characterized by bladder pain, urinary urgency and nocturia where few IC treatments exist and no approved therapies are available for PBS. Today, there are an estimated 10.5 million women and men in North America who suffer from PBS/IC.

About Urigen Pharmaceuticals, Inc.

Urigen Pharmaceuticals is a specialty pharmaceutical company dedicated to the development and commercialization of therapeutic products for urological disorders. Urigen's product development programs target significant unmet medical needs and major market opportunities in urology. URG101 targets Painful Bladder Syndrome/Interstitial Cystitis, which affects approximately 10.5 million men and women in North America. URG301 targets urethritis and acute urgency in patients diagnosed with an overactive bladder. For further information, please visit Urigen's website at http://www.urigen.com.

Forward-Looking Statement

This press release may contain forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential" or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events, or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors associated with our Company, please review our SEC filings.

Contact:

Urigen Pharmaceuticals, Inc.

Martin E. Shmagin

Chief Financial Officer

http://www.urigen.com


'/>"/>
SOURCE Urigen Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. WallSt.net Announces Upcoming Interview with CSO and COO of Urigen Pharmaceuticals
2. Dr. Lisa Zdinak Announces, CO2TouchTM Brazilian Carboxytherapy - New Technology for Non-Surgical Treatment of Stretch Marks, Cellulite and Dark Undereye Circles
3. Trubion Pharmaceuticals Announces Appointment of New Chief Medical Officer
4. Medco Announces Research Collaboration with FDA Focused on Personalized Medicine
5. AMDL Announces Teleconference to Discuss Its Second Quarter 2008 Financial Results
6. Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
7. Sun Pharma Announces U.S. FTC Clearance for Taro Tender Offer
8. Pregis Announces Second Quarter 2008 Financial Results
9. WuXi PharmaTech Announces Second Quarter 2008 Results
10. Assurant Announces Two Executive Appointments
11. Lotus Pharmaceuticals Announces Conference Call to Discuss Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... MB Business Capital, a ... senior credit facility to Sunrise, Florida-based Management Health Systems, LLC, dba MedPro Healthcare ... a recapitalization of MedPro led by Harren Equity Partners. Brightwood Capital Advisors ...
(Date:1/19/2017)... Texas (PRWEB) , ... January 19, 2017 , ... Students ... GenCure Tissue Donation Awareness Scholarship competition., The winner will earn a $1,000 scholarship and ... The competition begins Feb. 1, and the deadline is May 31, with the winner ...
(Date:1/19/2017)... ... January 19, 2017 , ... Ultimate Medical Academy (UMA) is ... passionate about making a difference in the lives of the next generation of ... nonprofit healthcare educational institution, has more than 30,000 alumni and employs more than ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... ... asset protection and financial planning services to communities throughout eastern Georgia, is embarking ... against heart disease. , Heart disease kills more Americans every year than anything ...
(Date:1/19/2017)... ... 2017 , ... St. Catherine’s Village announced that a limited number of rooms ... facility on the grounds of the St. Catherine’s Village campus in Madison, Mississippi that ... nursing home in Mississippi for the second year in a row by readers of ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017 This report on the opioid induced ... of the global market. Large number of chronic pain ... constipation is a major side effect of consumption of ... targeted therapy has been prescribed to treat opioid induced ... medicines, and growing awareness about the therapy are the ...
(Date:1/19/2017)... YORK , January 19, 2017 According ... market for cryotherapy is set to witness a CAGR of 6.5% ... North America will continue to be the leading market ... ... Suppliers are emphasizing on ensuring affordable and adequate supply of ...
(Date:1/19/2017)... 2017  Sensus Healthcare, Inc. (NASDAQ: ... the treatment of non-melanoma skin cancers and other ... therapy, today announced that it will report its ... on Thursday, February 2, 2017 after the market close. ... call with the investment community on Thursday, February 2, ...
Breaking Medicine Technology: